Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Tempus AI (TEM) Price & Performance

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETFTrade

Price performance (Past 24H)

Key statistics

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Tempus AI — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.82, while Tempus AI trades at $46.96 (market cap $8.80B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.

PDBCTEM
52-Week High
$18.91$103.25
52-Week Low
$12.90$42.37
Market Cap
$8.80B
Sector
Broad Market / Factor
Enterprise Value
$9.47B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.65, up 2.32% today, reflecting strong commodity momentum. The technical outlook is bullish with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent news highlights institutional accumulation, such as Geneos Wealth Management increasing its stake by 150.6% in Q1 2026 (Defense World, 2026-07-19). The fund has delivered significant returns, up 37% since March 2024, driven by energy price surges and supply disruptions.

The outlook for PDBC remains positive as a diversified commodities play and inflation hedge, but risks include commodity price volatility and the fund's structural costs. Momentum may weaken if oil prices retreat, as noted in a recent downgrade to hold (Seeking Alpha, 2026-06-11). Investors should weigh the fund's tax advantages against roll costs and cyclical commodity exposure.

Tempus AI

Tempus AI (TEM) trades at $48.41, down 7.74% amid market reaction to its $1.5 billion acquisition of Personalis. The stock shows bearish technical signals with negative moving averages and oversold RSI levels. Fundamentally, the company maintains strong revenue growth ($1.27B in 2025) but faces significant losses (-$245M net income) and negative margins. Recent news highlights strategic expansion in cancer diagnostics through AI-driven platforms.

Despite analyst optimism (61.5% buy ratings, $68.50 target), TEM faces execution risks from the major acquisition and persistent profitability challenges. The stock's current discount to target offers potential upside if integration succeeds, but high cash burn and competitive pressures require careful monitoring for investors considering entry at these levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.

Read more on PDBC

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Read more on TEM